The factor that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting sleep apnoea or death from sleep apnoea with the circumstances of a personâ€™s relevant service is: (A) for obstructive sleep apnoea only, (i) having chronic obstruction or chronic narrowing of the upper airway at the time of the clinical onset of sleep apnoea; or (ii) being obese at the time of the clinical onset of sleep apnoea; or (iii) having hypothyroidism at the time of the clinical onset of sleep apnoea; or (iv) having acromegaly at the time of the clinical onset of sleep apnoea; or (v) being treated with antiretroviral therapy for human immunodeficiency virus infection before the clinical onset of sleep apnoea; or (B) for central sleep apnoea only, (i) having congestive cardiac failure at the time of the clinical onset of sleep apnoea; or (ii) using a long-acting opioid at an average daily morphine equivalent dose of at least 75 milligrams for at least the two months before the clinical onset of sleep apnoea; or (C) having a central nervous system lesion or disorder involving the upper or mid-cervical cord, brain stem, cerebrum or extrapyramidal system at the time of the clinical onset of sleep apnoea; or (D) having autonomic neuropathy at the time of the clinical onset of sleep apnoea; or (E) having chronic renal disease requiring renal transplantation or dialysis at the time of the clinical onset of sleep apnoea; or (F) having a neuromuscular disease affecting the diaphragm, other respiratory muscles or upper airway muscles at the time of the clinical onset of sleep apnoea; or (G) being treated daily with an atypical antipsychotic drug, for a condition for which the drug cannot be ceased or substituted, for at least the two months before the clinical onset of sleep apnoea; or (H) for obstructive sleep apnoea only, (i) having chronic obstruction or chronic narrowing of the upper airway at the time of the clinical worsening of sleep apnoea; or (ii) being obese at the time of the clinical worsening of sleep apnoea; or (iii) having hypothyroidism at the time of the clinical worsening of sleep apnoea; or (iv) having acromegaly at the time of the clinical worsening of sleep apnoea; or (v) being treated with antiretroviral therapy for human immunodeficiency virus infection before the clinical worsening of sleep apnoea; or (I) for central sleep apnoea only, (i) having congestive cardiac failure at the time of the clinical worsening of sleep apnoea; or (ii) using a long-acting opioid at an average daily morphine equivalent dose of at least 75 milligrams for at least the two months before the clinical worsening of sleep apnoea; or (J) having a central nervous system lesion or disorder involving the upper or mid-cervical cord, brain stem, cerebrum or extrapyramidal system at the time of the clinical worsening of sleep apnoea; or (K) having autonomic neuropathy at the time of the clinical worsening of sleep apnoea; or (L) having chronic renal disease requiring renal transplantation or dialysis at the time of the clinical worsening of sleep apnoea; or (M) having a neuromuscular disease affecting the diaphragm, other respiratory muscles or upper airway muscles at the time of the clinical worsening of sleep apnoea; or (N) being treated daily with an atypical antipsychotic drug, for a condition for which the drug cannot be ceased or substituted, for at least the two months before the clinical worsening of sleep apnoea; or (O) consuming an average of at least 30 grams of alcohol per day for at least the six months before the clinical worsening of sleep apnoea; or (P) inability to obtain appropriate clinical management for sleep apnoea.